Printer Friendly
The Free Library
14,694,658 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Browse RNA interference topic

Subtopics (21)

 

Articles

1-100 out of 100 article(s)
Title Author Type Date Words
Therapeutic applications of RNAi; methods and protocols. Book review Dec 1, 2009 133
RXi Pharmaceuticals Wins 2009 RNAi Technology Innovation of the Year Award from Frost & Sullivan. Nov 23, 2009 733
Alnylam Presents New Pre-clinical Data on ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancer. Nov 18, 2009 1185
United States : Alnylam Eyes RNAi for Manufacturing Drugs. Nov 13, 2009 213
Alnylam Provides Update on RNAi Pipeline, Platform, and Technology at Its R&D Day. Nov 12, 2009 1745
Alnylam Presents New Pre-Clinical Data on RNAi Therapeutics at Oligonucleotides Therapeutics Society (OTS) Meeting. Nov 5, 2009 1574
Alnylam and Roche Advance RNAi Therapeutic Collaboration Phase of Landmark 2007 Alliance. Nov 4, 2009 1001
RXi Pharmaceuticals to Present Data Demonstrating the Robust Performance of its RNAi Therapeutics Platform at Upcoming Scientific Conference. Conference news Nov 3, 2009 685
Alnylam Presents New Pre-Clinical Data on ALN-TTR, an RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis. Nov 2, 2009 1169
RXI ACQUIRES OWNERSHIP OF PREVIOUSLY LICENSED RNAI DELIVERY. Nov 1, 2009 530
Alnylam Grants KOKEN License to Kreutzer-Limmer Patents for the RNA Interference (RNAi) Research Products Market. Oct 27, 2009 980
RXi Pharmaceuticals Obtains Direct Ownership of Previously Licensed RNAi Delivery Intellectual Property. Sep 25, 2009 749
Alnylam and Medtronic Present New Late-Stage Pre-clinical Data on ALN-HTT, an RNAi Therapeutic for the Treatment of Huntington's Disease. Sep 15, 2009 1458
RXi Pharmaceuticals' Self-delivering rxRNAs Demonstrate Superior Drug Properties Compared to Classic RNAi Compounds in Animal Studies. Sep 15, 2009 801
Alnylam Announces Allowance in Europe of New Fundamental Patent Broadly Covering RNAi Therapeutics in Oncology. Sep 9, 2009 1820
Thermo Fisher Scientific Establishes RNAi Discovery Grant Program to Advance Gene Research. Aug 13, 2009 530
RXi Pharmaceuticals Presented Data from Animal Trials Demonstrating the Utility of Self-Delivering RNAi at IBC's Oligonucleotide Therapeutics Conference. Conference news Aug 5, 2009 821
RXi Pharmaceuticals Acquires Exclusive License to Proprietary, Potentially Paradigm-Changing RNAi Delivery Technology from Advirna LLC. Jul 27, 2009 915
Archemix and Dicerna to Collaborate on Conjugated Aptamer-Dicer Substrate RNAi Therapeutics. Jul 21, 2009 806
Alnylam Announces Extension of RNAi Therapeutics Collaboration with Novartis. Jul 17, 2009 853
Alnylam and Collaborators Present New Pre-Clinical Research Findings on RNAi Therapeutics Targeting PCSK9, a Genetically Validated Regulator of LDL Metabolism. Jun 18, 2009 1181
Intradigm announces issuance of RNA interference (RNAi) patent covering potent siRNA sequence. Jun 1, 2009 621
RXi Pharmaceuticals Presented Breakthrough RNAi Delivery Technologies at the TIDES[R] 2009 Conference. May 21, 2009 858
RXi Pharmaceuticals Announces Publication in Nature of Positive Pre-clinical Data Demonstrating that Oral Administration of RNAi Therapeutics Effectively Reduces Systemic Inflammatory Response. Apr 30, 2009 1419
Isis and Alnylam Form New Collaboration to Develop Single-Stranded RNAi Technology. Apr 29, 2009 1563
Alnylam Granted New Fundamental Patent in China Broadly Covering RNAi Therapeutics. Apr 27, 2009 1826
Alnylam Announces Allowance in Europe of New Fundamental Patent Broadly Covering RNAi Therapeutics. Apr 20, 2009 1793
Is RNA interference involved in plant-fungal symbiosis? Brief article Apr 1, 2009 259
RXi Pharmaceuticals to Present at the RNAi, MicroRNAs - 2009 - Boston Meeting. Mar 30, 2009 617
Dicerna Pharmaceuticals Secures Exclusive Worldwide Right to Sublicense the Dicer Substrate Technology[TM] RNAi Platform. Mar 18, 2009 538
Alnylam and Collaborators at MIT Publish New In Vivo Research on Systemic Delivery of RNAi Therapeutics. Mar 5, 2009 1098
Alnylam and Collaborators Present Data from Multiple Pre-Clinical and Clinical Programs at RNAi Keystone Symposium. Feb 12, 2009 2643
Alnylam and Collaborators Publish New Pre-Clinical Research Demonstrating In Vivo Efficacy of Systemically Delivered RNAi Therapeutics in Ovarian Cancer. Feb 11, 2009 1640
Alnylam Receives Grant of New Patent Broadly Covering RNAi Therapeutics. Feb 10, 2009 1569
Research and Markets: Recently Updated Report Examines the Fundamentals of RNAi's Technologies, Markets and Companies. Report Feb 10, 2009 597
Regulatory noncoding RNAs at Hox loci. Brock, Hugh W.; Hodgson, Jacob W.; Petruk, Svetlana; Mazo, Alexander Report Feb 1, 2009 6533
Alnylam and Cubist Form Strategic Collaboration to Develop and Commercialize RNAi Therapeutics Targeting Respiratory Syncytial Virus (RSV) Infection. Jan 9, 2009 2007
Alnylam Advances RNAi Therapeutics Pipeline and Files Company's First Systemic Delivery IND. Dec 23, 2008 1180
Alnylam Publishes Pre-Clinical Research on Direct CNS Delivery of RNAi Therapeutics. Dec 19, 2008 968
Invitrogen Launches In Vivo RNAi Delivery Reagent. Nov 19, 2008 587
IMM, Cenix, and Alnylam Discover New Targets in Malaria Infection with RNAi Technology. Nov 11, 2008 1415
Alnylam and Collaborators Publish Research on a New Class of Chemically Modified RNAi Therapeutics that Target Two Distinct Cellular Mechanisms. Nov 3, 2008 1305
Dicerna Pharmaceuticals, an RNA Interference Company, to Present at Discovery on Target Conference. Conference news Oct 22, 2008 609
Anastasia Khvorova, Ph.D., a Leading Scientist in the RNAi Industry, Joins RXi Pharmaceuticals as Chief Scientific Officer. Oct 22, 2008 704
CytRx Corporation's 45% Owned Affiliate RXi Pharmaceuticals Obtains an Exclusive Worldwide License to Technology for the Oral Delivery of RNAi Therapeutics from the University of Massachusetts Medical School. Oct 15, 2008 865
RXi Pharmaceuticals Obtains an Exclusive Worldwide License to Technology for the Oral Delivery of RNAi Therapeutics from the University of Massachusetts Medical School. Oct 14, 2008 745
Alnylam Forms Collaboration with Max Planck Institute to Investigate Biological Mechanisms for Cellular Uptake of RNAi Therapeutics. Aug 11, 2008 1016
United States: Alnylam Awarded Continued Funding Under U.S. Government Contract to Develop RNAi Therapeutics for Biological Threats. Aug 7, 2008 415
Alnylam Awarded Continued Funding Under U.S. Government Contract to Develop RNAi Therapeutics for Biological Threats. Aug 6, 2008 1287
Alnylam Grants New InterfeRx(TM) Intellectual Property License to Calando for Development and Commercialization of RNAi Therapeutics. Jul 21, 2008 1066
Alnylam Announces Extension of RNAi Therapeutics Collaboration with Novartis. Jul 16, 2008 902
Thermo steps up RNAi market presence. Jul 15, 2008 145
Dicerna Pharmaceuticals, a Second Generation RNA Interference Company, Completes Second Closing of Series A Financing; Unveils Strategic Focus. Jul 15, 2008 844
Thermo Fisher Scientific Acquires Open Biosystems, Creating Unmatched RNAi Platform. Jul 1, 2008 521
Silence Receives Allowance for its Core RNAi Patent. Jul 1, 2008 858
Apoptosis and pathogenesis of melanoma and nonmelanoma skin cancer. Report Jul 1, 2008 405
Dicerna Pharmaceuticals, a RNA Interference Company, to Present at 9th Annual Beyond Genome Conference. Conference news Jun 9, 2008 372
Intradigm Announces Allowance of Key RNA Interference Patent Patent Covers Small Interfering RNA Structural Features Tied to Increased Efficacy and Potency of RNAi Therapeutics. Jun 1, 2008 797
Alnylam and Takeda Form Strategic Worldwide Platform Alliance in RNAi Therapeutics. May 27, 2008 1555
Alnylam and Collaborators Publish In Vivo Research on Validation of a Mammalian Host Gene Involved in Malaria Infection and on the Anti-Parasitic Efficacy of RNAi Therapeutics. May 21, 2008 1128
Calando Granted Broad Patent Rights to RNAi Technology in China. May 13, 2008 833
Alnylam and Collaborators at MIT Publish Research on the Discovery of 'Lipidoids', a Novel Class of Lipid-Based Molecules for the Delivery of RNAi Therapeutics. Apr 28, 2008 1522
RNAi Efficacy Against ALS (Lou Gehrig's Disease) in a Research Model Published in Peer-Reviewed Journal; RXi Pharmaceuticals Exclusive Licensee of Research. Apr 10, 2008 805
Nastech Pharmaceutical Company Inc. to Present RNAi Data. Mar 25, 2008 843
Alnylam Grants Shanghai GenePharma License to Kreutzer-Limmer Patents for the RNA Interference (RNAi) Research Products Market. Mar 20, 2008 1096
RXi Pharmaceuticals to Present Data on the Cellular Mechanism of RNAi Interference at Keystone Symposia's RNAi, MicroRNA, and Non-Coding RNA Meeting. Mar 20, 2008 571
RNAi dispute resolved. Mar 15, 2008 79
Nastech Pharmaceutical Company Inc. Completes Key RNAi Patent Filings. Mar 11, 2008 907
Nastech Pharmaceutical Company Inc. Announces Scientific Advisory Board for MDRNA, Inc., its Wholly-Owned RNAi Subsidiary. Mar 7, 2008 1431
Alnylam Achieves First Human Proof of Concept for an RNAi Therapeutic with GEMINI Study. Feb 29, 2008 1692
Rxi Pharmaceuticals exclusively licensed certain RNAi sequences. Feb 29, 2008 11
Alnylam to Webcast Conference Call to Discuss Phase II GEMINI Data for ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection. Feb 25, 2008 430
Alnylam Reports Pre-clinical Progress with RNAi Therapeutics in Neurological Disease. Feb 7, 2008 1043
Traversa Raises $2M to Advance RNAi Delivery in Angel-Led Series A Financing. Feb 4, 2008 552
Intradigm Strengthens RNA Interference (RNAi) Position with MIT License. Feb 1, 2008 434
SuperArray Bioscience licensed RNAi patents. Jan 31, 2008 9
Alnylam Announces Grant of New Patent Covering RNAi Therapeutics in the United Kingdom. Jan 28, 2008 1717
Alnylam Reports Positive Phase II Data for ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection. Jan 23, 2008 1089
Alnylam Launches its RNAi 2010 Outlook for Key Scientific, Clinical, and Business Initiatives; Announces Goals and Guidance for 2008. Jan 7, 2008 1822
Alnylam Announces Continued Progress on Development of its Intellectual Property Estate Covering RNAi Therapeutics. Jan 3, 2008 1762
Promega increased its stake in RNAi provider Benetec to 6.15%. Dec 15, 2007 20
RXi Pharmaceuticals Licenses Rights to RNAi Sequences to Genes for Therapeutic Applications from Thermo Fisher Scientific. Dec 14, 2007 915
Alnylam Announces Grant of Broad Patent Covering RNAi Therapeutics in Germany. Nov 26, 2007 1584
Invitrogen and CytRx Subsidiary RXi Pharmaceuticals Collaborate to Enhance RNAi Technologies for Therapeutic Applications. Nov 14, 2007 918
SuperArray Bioscience licenses RNA interference patent from The Carnegie Institution. Nov 1, 2007 398
Alnylam and Collaborators Publish New Pre-clinical Results on RNAi Therapeutics for the Treatment of Huntington's Disease. Oct 17, 2007 1007
Alnylam Presents First Ever Non-Human Primate Data with an RNAi Therapeutic Targeting PCSK9 Showing Significant and Durable Reductions in LDL Cholesterol Levels. Oct 8, 2007 1415
Alnylam Grants GeneDesign License to Kreutzer-Limmer Patents for the RNA Interference (RNAi) Research Products Market. Oct 3, 2007 990
Alnylam and Collaborators Publish New Paper in the Journal Nature on the In Vivo Efficacy and Safety of RNAi Therapeutics. Sep 26, 2007 1049
Disease-regulated RNA interference for spinocerebellar ataxia type-1. Liu, Gumei Brief article Sep 22, 2007 249
Alnylam and Collaborators Publish New Research on the In Vivo Mechanisms for Systemic Delivery of RNAi Therapeutics. Sep 17, 2007 1112
Alnylam Pharmaceutical granted Hayahi Kasei a license to provide RNAi. Sep 15, 2007 19
Patent Application Licensed to CytRx Subsidiary RXi Pharmaceuticals Issues in Australia With Broad Claims to Expressed RNAi. Sep 5, 2007 805
Patent Application Licensed to RXi Pharmaceuticals Issues in Australia with Broad Claims to Expressed RNAi. Sep 5, 2007 575
Alnylam Awarded $38.6 Million U.S. Government Contract to Develop RNAi Therapeutics for Biological Threats. Aug 9, 2007 1242
Mello promotes RNAi research; Nobel Prize winner says tool would revolutionize medicine. Aug 9, 2007 530
Quark files patent application covering chemical modifications to its RNAi molecules. Aug 1, 2007 431
Alnylam and Medtronic Advance Collaboration on Drug-Device Combinations with RNAi Therapeutics for CNS Diseases. Jul 30, 2007 1109
Examine the Outlook for RNAi, 2007: siRNA and miRNA in Biology, Diagnostics and Therapeutics. Jul 20, 2007 563
Valosin-containing protein from the hard tick Haemaphysalis longicornis: effects of dsRNA-mediated HlVCP gene silencing. Boldbaatar, Damdinsuren; Battsetseg, Badgar; Hatta, Takeshi; Miyoshi, Takeharu; Tsuji, Naotoshi; Xua Report Jun 1, 2007 5367

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles